Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915

α-Synuclein in Lewy bodies

Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium

McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411

α-Synuclein Locus Triplication Causes Parkinson's Disease

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop

McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960

Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy

Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024

Levodopa and the Progression of Parkinson's Disease

The Parkinson Study Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,844

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease

Farotti, L., Paciotti, S., Tasegian, A., Eusebi, P., & Parnetti, L. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1341312 · Cited by 25

Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives

Wu, J., Cao, C., Loch, R. A., Tiiman, A., & Luo, J. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000086 · Cited by 24

Use of 3D Printing Techniques to Fabricate Implantable Microelectrodes for Electrochemical Detection of Biomarkers in the Early Diagnosis of Cardiovascular and Neurodegenerative Diseases

Zilinskaite, N., Shukla, R. P., & Baradokė, A. (2023) · ACS Measurement Science Au · doi:10.1021/acsmeasuresciau.3c00028 · Cited by 23

Analysis of Alpha-Synuclein in Malignant Melanoma – Development of a SRM Quantification Assay

Welinder, C., Jönsson, G. B., Ingvar, C., Lundgren, L., Baldetorp, B., Olsson, H. L., Breslin, T., Rezeli, M., Jansson, B., Fehniger, T. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110804 · Cited by 24

Gold nanoparticles as a label-free probe for the detection of amyloidogenic protein

Zhang, H., Zheng, H., Long, Y., Xiao, G., Zhang, L., Wang, Q.-L., Gao, M., & Bai, W. (2011) · Talanta · doi:10.1016/j.talanta.2011.12.052 · Cited by 24

Resting state activity and connectivity of the nucleus basalis of Meynert and globus pallidus in Lewy body dementia and Parkinson's disease dementia

Gratwicke, J., Oswal, A., Akram, H., Jahanshahi, M., Hariz, M. I., Zrinzo, L. U., Foltynie, T., & Vladimir Litvak, A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117184 · Cited by 23

Detection and assessment of alpha-synuclein in Parkinson disease

Tsao, H.-H., Huang, C., & Wu, Y. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105358 · Cited by 23

Combined Analysis of CSF Tau, A β 42, A β 1–42% and A β 1– 40ox % in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

Bibl, M., Esselmann, H., Lewczuk, P., Trenkwalder, C., Otto, M., Kornhuber, J., Wiltfang, J., & Mollenhauer, B. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/761571 · Cited by 22

How many biomarkers to discriminate neurodegenerative dementia?

Sancesario, G. M., & Bernardini, S. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1051658 · Cited by 23

Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases

Halperin, I. J. Y., Morelli, M., Korczyn, A. D., Youdim, M. B. H., & Mandel, S. A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.033 · Cited by 22

Default mode network connectivity is linked to cognitive functioning and CSF Aβ1–42 levels in Alzheimer’s disease

Çelebi, Ö. Ö., Uzdoğan, A., Oğuz, K. K., Has, A. C., Dolgun, A., Çakmaklı, G. Y., Akbıyık, F., Elibol, B., & Saka, E. (2015) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2015.09.010 · Cited by 21

Parkinson's disease – the continuing search for biomarkers

Breen, D. P., Michell, A. W., & Barker, R. A. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.080 · Cited by 21

Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study

Li, X., Yang, W., Li, X., Li, X., Li, W., Song, Q., Sun, L., Lin, F., Chen, Z., Wang, C., et al. (2020) · Parkinson s Disease · doi:10.1155/2020/8740419 · Cited by 23

Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease

Lowes, H., Kurzawa-Akanbi, M., Pyle, A., & Hudson, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-72190-5 · Cited by 21

Erythrocytic α-Synuclein Species for Parkinson’s Disease Diagnosis and the Correlations With Clinical Characteristics

Yu, Z., Liu, G., Li, Y., Arkin, E., Zheng, Y., & Feng, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.827493 · Cited by 21

Proteomics as a new paradigm to tackle Parkinson’s disease research challenges

Licker, V., & Burkhard, P. R. (2014) · Translational Proteomics · doi:10.1016/j.trprot.2014.08.001 · Cited by 21

Exacerbated neuronal ceroid lipofuscinosis phenotype in Cln1/5 double knock-out mice

Blom, T., Schmiedt, M.-L., Wong, A. M. S., Kyttälä, A., Soronen, J., Jauhiainen, M., Tyynelä, J., Cooper, J. D., & Jalanko, A. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010140 · Cited by 24

Specific Changes of Serum Proteins in Parkinson's Disease Patients

Lu, W., Wan, X., Liu, B., Rong, X., Zhu, L., Li, P., Li, J., Wang, L., Cui, L., & Wang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095684 · Cited by 22

α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies

Ballard, C. G., Jones, E. L., Londos, E., Minthon, L., Francis, P. T., & Aarsland, D. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209991049 · Cited by 21

Neurochemical biomarkers in Alzheimer’s disease and related disorders

Bibl, M., Esselmann, H., & Wiltfang, J. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612455367 · Cited by 22

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein

Abdi, I. Y., Majbour, N. K., Willemse, E. A. J., van de Berg, W. D. J., Mollenhauer, B., Teunissen, C. E., & El‐Agnaf, O. M. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638718 · Cited by 20

Progress towards a molecular biomarker for Parkinson disease

Foulds, P. G., Mann, D. M. A., Mitchell, J. D., & Allsop, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.78 · Cited by 21

Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits

Benetti, F., Gustincich, S., & Legname, G. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.659661 · Cited by 22

Missense Mutations Modify the Conformational Ensemble of the α-Synuclein Monomer Which Exhibits a Two-Phase Characteristic

Guzzo, A., Delarue, P., Rojas, A. V., Nicolaı̈, A., Maisuradze, G. G., & Senet, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.786123 · Cited by 21

The Potential of Pathological Protein Fragmentation in Blood-Based Biomarker Development for Dementia – With Emphasis on Alzheimer’s Disease

Inekci, D., Jonesco, D. S., Kennard, S., Karsdal, M. A., & Henriksen, K. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00090 · Cited by 19

Clinical indications for analysis of Alzheimer's disease CSF biomarkers

Engelborghs, S. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.024 · Cited by 20

The role of α-synuclein in neurodegeneration — An update

Jellinger, K. A. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0013-1 · Cited by 19

Cellular prion protein is present in dopaminergic neurons and modulates the dopaminergic system

Rial, D., Pamplona, F. A., Moreira, E. L. G., Moreira, K. D. M., Hipólide, D. C., Rodrigues, D. I., Dombrowski, P. A., Cunha, C. D., Agostinho, P. M., Takahashi, R. N., et al. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12600 · Cited by 19

An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression

Li, Y., Stewart, T., Shi, M. Y., Pottiez, G., Dator, R., Wu, R., Aro, P., Schuster, R. J., Ginghină, C., Pan, C., et al. (2017) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700045 · Cited by 20

Phosphorylated α-synuclein as a potential biomarker for Parkinson’s disease and related disorders

Foulds, P. G., Mann, D. M. A., & Allsop, D. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.5 · Cited by 18

Application of peptide biomarkers in life analysis based on liquid chromatography–mass spectrometry technology

Han, T., Cong, H., Yu, B., & Shen, Y. (2022) · BioFactors · doi:10.1002/biof.1875 · Cited by 18

Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets

Kawahata, K., & Fukunaga, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317037 · Cited by 17

Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases

Nutu, M., Bourgeois, P., Zetterberg, H., Portelius, E., Andréasson, U., Parent, S., Lipari, F., Hall, S., Constantinescu, R., Hansson, O., et al. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8208-8 · Cited by 19

Problems Associated With Fluid Biomarkers for Parkinson‘s Disease

Nyhlén, J., Constantinescu, R., & Zetterberg, H. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.84 · Cited by 19

Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease

Mattsson, N., Insel, P. S., Tosun, D., Zhang, J., Jack, C. R., Galasko, D. R., Weiner, M. W., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085443 · Cited by 18

Nanoparticle-based colorimetric sensors to detect neurodegenerative disease biomarkers

Fan, Q., Gao, Y., Mazur, F., & Chandrawati, R. (2021) · Biomaterials Science · doi:10.1039/d1bm01226f · Cited by 17

Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms

Petricca, L., Chiki, N., Hanna-El-Daher, L., Aeschbach, L., Burai, R., Stoops, E., Fares, M.-B., & Lashuel, H. A. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223285 · Cited by 16

Spreading of alpha-synuclein between different cell types

Ruf, W. P., Meirelles, J. L., & Danzer, K. M. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114059 · Cited by 19

From protein biomarkers to proteomics in dementia with Lewy Bodies

Tsamourgelis, A., Swann, P., Chouliaras, L., & O'Brien, J. T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101771 · Cited by 18

Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique

Kawahata, K., Sekimori, T., Oizumi, H., Takeda, A., & Fukunaga, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713267 · Cited by 17

Microglia‐Derived Vitamin D Binding Protein Mediates Synaptic Damage and Induces Depression by Binding to the Neuronal Receptor Megalin

Kong, Y., Zhang, X., Li, L., Zhao, T., Huang, Z., Zhang, A., Sun, Y., Jiao, J., Zhang, G., Liu, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202410273 · Cited by 17

Emerging Biomarkers in Cognition

Wicklund, M. R., & Petersen, R. C. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.006 · Cited by 17

Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies

Bousiges, O., & Blanc, F. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.11.027 · Cited by 18

Wild-Type α-Synuclein and Variants Occur in Different Disordered Dimers and Pre-Fibrillar Conformations in Early Stage of Aggregation

Guzzo, A., Delarue, P., Rojas, A. V., Nicolaı̈, A., Maisuradze, G. G., & Senet, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.910104 · Cited by 18

The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research

Kansal, K., & Irwin, D. J. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.02.002 · Cited by 18

Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of experimental neurodegenerative diseases

Ebert, S., Goos, M., Rollwagen, L., Baake, D., Zech, W., Esselmann, H., Wiltfang, J., Mollenhauer, B., Schliebs, R., Gerber, J., et al. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22270 · Cited by 17

Using Gastrocnemius sEMG and Plasma α-Synuclein for the Prediction of Freezing of Gait in Parkinson's Disease Patients

Wang, X., Kang, W., Yang, Q., Zhang, L.-Y., Chen, S., & Liu, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089353 · Cited by 17

Pros and cons of a prion-like pathogenesis in Parkinson's disease

Hilker, R., Brotchie, J. M., & Chapman, J. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-74 · Cited by 16

Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson’s disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings

Katayama, T., Sawada, J., Kikuchi, S., Kano, K., Takahashi, K., Saito, T., Okizaki, A., & Hasebe, N. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134564 · Cited by 16

Biomarkers in Parkinson‘s Disease: A Funder‘s Perspective

Frasier, M. A., Chowdhury, S., Eberling, J. L., & Sherer, T. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.89 · Cited by 16

Cerebrospinal fluid α‐synuclein levels in Parkinson's disease – changed or unchanged?

Zetterberg, H., Petzold, M., & Magdalinou, N. K. (2013) · European Journal of Neurology · doi:10.1111/ene.12326 · Cited by 15

Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation

Hirohata, M., Ono, K., Morinaga, A., Ikeda, T., & Yamada, M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.01.005 · Cited by 15

Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid

Kruse, N., & Mollenhauer, B. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.08.003 · Cited by 14

Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease

Cedarbaum, J. M., Crans, G., & Grundman, M. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0069-y · Cited by 14

Serum peptides as candidate biomarkers for dementia with Lewy bodies

Suzuki, I., Noguchi, M., Arito, M., Sato, T., Omoteyama, K., Maedomari, M., Hasegawa, H., Suematsu, N., Okamoto, K., Kato, T., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4274 · Cited by 14

Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease

Grünblatt, E. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.12.1865 · Cited by 14

Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease

Chelpin, M. V. E., Söderberg, L., Fälting, J. M., Möller, C., Giorgetti, M., Constantinescu, R., Blennow, K., Zetterberg, H., & Höglund, K. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202141 · Cited by 13

Decreased levels of alpha‐synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis

Antonelou, R. C., Emmanouilidou, E., Gasparinatos, G., Velona, T., Voumvourakis, K. I., & Stefanis, L. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13163 · Cited by 13

Cerebrospinal Fluid, Imaging, and Physiological Biomarkers in Dementia With Lewy Bodies

Mavroudis, I. A., Petridis, F., & Kazis, D. A. (2019) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519869700 · Cited by 14

Drug Targets from Genetics: Alpha-Synuclein

Danzer, K. M., & McLean, P. J. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247867 · Cited by 13

Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson’s disease

Chawla, S., Kalyane, D., Tambe, V., Deb, P. K., Kalia, K., & Tekade, R. K. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.005 · Cited by 12

Decreased plasma α-synuclein in idiopathic Parkinson’s disease patients after adjusting hemolysis factor

Shim, K. H., Kim, S. C., Youn, Y. C., Sung, Y. H., & An, S. S. A. (2020) · Molecular & Cellular Toxicology · doi:10.1007/s13273-020-00104-7 · Cited by 11

Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders

Initiative, A. D. N., Li, J., Bi, Y., Shen, X., Wang, H.-F., Xu, W., Tan, C., Dong, Q., Wang, Y., Tan, L., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00222-1 · Cited by 12

Serological Analysis of Alpha-synuclein and NF- κ B in Parkinson’s Disease Patients

Gupta, V. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/12545.5978 · Cited by 12

Immune responses to oligomeric α-synuclein in Parkinson’s disease peripheral blood mononuclear cells

Vega-Benedetti, A. F., Porcedda, C., Ercoli, T., Fusco, G., Burgaletto, C., Pillai, R., Palmas, F., Cantone, A. F., Angius, F., Solla, P., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12554-3 · Cited by 13

Biosensors for Parkinson’s Disease: Where Are We Now, and Where Do We Need to Go?

Maddocks, G. M., Eisenstein, M. S., & Soh, H. T. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00790 · Cited by 12

A Genome-Wide Association Study of α-Synuclein Levels in Cerebrospinal Fluid

Initiative, A. D. N., Zhong, X.-L., Li, J., Sun, L. J., Li, Y., Wang, H.-F., Cao, X., Tan, C., Wang, L., Tan, L., et al. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9922-2 · Cited by 11

Interlaboratory validation of cerebrospinal fluid α‐synuclein quantification in the diagnosis of sporadic Creutzfeldt‐Jakob disease

Kruse, N., Heslegrave, A., Gupta, V., Foiani, M. S., Villar‐Piqué, A., Schmitz, M., Lehmann, S., Teunissen, C. E., Blennow, K., Zetterberg, H., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.06.005 · Cited by 11

REM Sleep Behavior Disorder as a Prodromal Synucleinopathy: Updates on Clinical and Laboratory Biomarkers, and Implications for Neuroprotective Trials

Neilson, L. E., Khattab, Y. I., & Lim, M. M. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01452-4 · Cited by 10

Sensitive electrochemical recognition of α‐synuclein protein in human plasma samples using bioconjugated gold nanoparticles: An innovative immuno‐platform to assist in the early stage identification of Parkinson's disease by biosensor technology

Aminabad, E. D., Hasanzadeh, M., Ahmadalipour, A., Mahmoudi, T., Feizi, M. A. H., Safaralizadeh, R., & Mobed, A. (2022) · Journal of Molecular Recognition · doi:10.1002/jmr.2952 · Cited by 10

Cerebrospinal fluid protein biomarkers in Parkinson's disease

Faizan, M., Sachan, N., Verma, O., Sarkar, A., Rawat, N., & Singh, M. P. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117848 · Cited by 9

Sleep-controlling neurons are sensitive and vulnerable to multiple forms of α-synuclein: implications for the early appearance of sleeping disorders in α-synucleinopathies

dos Santos, A. B., Skaanning, L. K., Thaneshwaran, S., Mikkelsen, E., Leguizamón, C. R. R., Skamris, T., Kristensen, M. P., Langkilde, A. E., & Kohlmeier, K. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04467-z · Cited by 10

A porous silicon immunoassay platform for fluorometric determination of α-synuclein in human cerebrospinal fluid

Lee, S.-W., Silajdžić, E., Hon, Y., Björkqvist, M., Kim, S., Jeong, O. C., Hansson, O., & Laurell, T. (2014) · Microchimica Acta · doi:10.1007/s00604-014-1180-2 · Cited by 10

Sensitive analysis of α-synuclein by nonlinear laser wave mixing coupled with capillary electrophoresis

Iwabuchi, M., Hetu, M. M., & Tong, W. G. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.01.010 · Cited by 10

Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases

Parnetti, L., Eusebi, P., & Lleó, A. (2016) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000445452 · Cited by 10

CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias

Ballard, C. G., & Jones, E. L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd6393 · Cited by 10

Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain

Trist, B. G., Wright, C. J., Rangel, A., Cottle, L., Prasad, A., Jensen, N. M., Gram, H., Dzamko, N. L., Jensen, P. H., & Kirik, D. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00830-y · Cited by 9

α-synuclein monoclonal antibodies in Parkinson's disease: A failed promise or unmet potential?

Messak, M., Abdelmageed, A., Khattab, Y. A., Altalab, G., Mandour, Y., & Shaker, O. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.125806 · Cited by 9

Low serum Α-SYNUCLEIN and oligomer Α-SYNUCLEIN levels in multiple sclerosis patients

Bilge, N., Şimşek, F., Yevgi, R., Ceylan, M., & Aşkın, S. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577432 · Cited by 9

Biomarkers for brain disorders

Ward, M. A., & Schofield, E. (2010) · Therapy · doi:10.2217/thy.10.31 · Cited by 9

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

Kruse, N., Schlossmacher, M. G., Schulz‐Schaeffer, W., Vanmechelen, E., Vanderstichele, H., El‐Agnaf, O. M. A., & Mollenhauer, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153564 · Cited by 9

Validation of a new assay for α-synuclein detection in cerebrospinal fluid

Førland, M. G. G., Öhrfelt, A., Oftedal, L., Tysnes, O., Larsen, J. P., Blennow, K., Zetterberg, H., Alves, G. W., & Lange, J. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0409 · Cited by 9

Cerebrospinal fluid in Creutzfeldt–Jakob disease

Zerr, I., Zafar, S., Schmitz, M., & Llorens, F. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00008-3 · Cited by 9

Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy

Abdelmotilib, H., & West, A. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0483-4 · Cited by 9

α-synuclein as a promising biomarker for developing diagnostic tools against neurodegenerative synucleionopathy disorders

Bagree, G., Silva, O. D., Liyanage, P. D., Ramarathinam, S. H., Sharma, S., Bansal, V., & Ramanathan, R. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.116922 · Cited by 11

Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders

Ho, G. J., Liang, W., Waragai, M., Sekiyama, K., Masliah, E., & Hashimoto, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/842475 · Cited by 9

Cerebrospinal Fluid α-Synuclein In the Differential Diagnosis of Parkinsonian Syndromes

Heegaard, N. H. H., Tanassi, J. T., Bech, S., Salvesen, L., Jensen, P. L., Montezinho, L. P., & Winge, K. (2014) · Future Neurology · doi:10.2217/fnl.14.51 · Cited by 9

CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies

Mollenhauer, B., & Schlossmacher, M. G. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.206391 · Cited by 9

Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion

Ding, Y., Wang, L., Liu, J., Deng, Y., Jiao, Y., & Zhao, A. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100040 · Cited by 8

Synuclein and Parkinson’s Disease: An Update

Jellinger, K. A. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737357-00175 · Cited by 9

An immunoassay for the quantification of phosphorylated α-synuclein at serine 129 in human cerebrospinal fluid

Silva, A. M., Hickford, E. S., & Cutler, P. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2407718 · Cited by 8

Analysis of Brain Protein Stability Changes in Mouse Models of Normal Aging and α-Synucleinopathy Reveals Age- and Disease-Related Differences

Ma, R., Johnson, J. H. R., Tang, Y., & Fitzgerald, M. C. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00653 · Cited by 8

CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies

Zhang, Q., Li, J., Quan, W., Liu, L., Qin, Y., Pei, X., Su, H., Xu, J., & Chen, J. (2022) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000516 · Cited by 8

Neuroimaging, Biomarkers, and Management of Dementia with Lewy Bodies

Hanagasi, H. A., Bılgıç, B., & Emre, M. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00151 · Cited by 8

What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease

Kühle, J., & Petzold, A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.592184 · Cited by 8

Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms

Winkel, I., Ermann, N., Żelwetro, A., Sambor, B., Mroczko, B., Kornhuber, J., Paradowski, B., & Lewczuk, P. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02351-x · Cited by 7

Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects

Blanc, F., & Bousiges, O. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.008 · Cited by 11

Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis

Kong, Y., Chen, Z., Wang, X. B., Wang, W., & Zhang, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220425 · Cited by 7

Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection

Kruse, N., & Mollenhauer, B. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9124-2_6 · Cited by 6

Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers

Tönges, L., Kwon, E. H., & Klebe, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.822949 · Cited by 9

S5‐01‐05: Quantification of total α‐synuclein in cerebrospinal fluid by ELISA: Cross‐sectional investigation of subjects with dementia and parkinsonism

Schlossmacher, M. G. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.574

Validation of a new assay for α-synuclein detection in cerebrospinal fluid

Førland, M. G. G., Öhrfelt, A., Oftedal, L., Tysnes, O., Larsen, J. P., Blennow, K., Zetterberg, H., Alves, G. W., & Lange, J. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0409 · Cited by 9

Validation of a new assay for alpha-synuclein detection in cerebrospinal fluid

Forland, M., Öhrfelt, A., Oftedal, L., Tysnes, O., Larsen, J., Blennow, K., Zetterberg, H., Alves, G., & Lange, J. (2017) · UCL Discovery (University College London)

P1‐358: A novel, highly sensitive and specific enyzme‐linked immunosorbent assay (ELISA) for the measurement of total human alpha‐synuclein in plasma and cerebrospinal fluid

Koehler, N. K. U., Stransky, E., Ruf, K., Laske, C., Richartz, E., Batra, A., & Buchkremer, G. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.940

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 143